These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 34061513)

  • 1. Docking Screens of Noncovalent Interaction Motifs of the Human Subtype-D2 Receptor-75 Schizophrenia Antipsychotic Complexes with Physicochemical Appraisal of Antipsychotics.
    Amani P; Habibpour R; Karami L; Hofmann A
    ACS Chem Neurosci; 2021 Jun; 12(12):2218-2232. PubMed ID: 34061513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palmitoylation of the carboxyl-terminal tail of dopamine D
    Zhang X; Kim KM
    Biochem Biophys Res Commun; 2016 Oct; 479(2):398-403. PubMed ID: 27659709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique effect of clozapine on adenosine A
    Valle-León M; Casajuana-Martin N; Del Torrent CL; Argerich J; Gómez-Acero L; Sahlholm K; Ferré S; Pardo L; Ciruela F
    Biomed Pharmacother; 2023 Apr; 160():114327. PubMed ID: 36736280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A QM protein-ligand investigation of antipsychotic drugs with the dopamine D2 Receptor (D2R).
    Ekhteiari Salmas R; Serhat Is Y; Durdagi S; Stein M; Yurtsever M
    J Biomol Struct Dyn; 2018 Aug; 36(10):2668-2677. PubMed ID: 28805144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.
    Masri B; Salahpour A; Didriksen M; Ghisi V; Beaulieu JM; Gainetdinov RR; Caron MG
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13656-61. PubMed ID: 18768802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-Like Receptor Agonist.
    Sánchez-Soto M; Bonifazi A; Cai NS; Ellenberger MP; Newman AH; Ferré S; Yano H
    Mol Pharmacol; 2016 Apr; 89(4):457-66. PubMed ID: 26843180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent haloperidol derivatives covalently binding to the dopamine D2 receptor.
    Schwalbe T; Kaindl J; Hübner H; Gmeiner P
    Bioorg Med Chem; 2017 Oct; 25(19):5084-5094. PubMed ID: 28666858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
    Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic haloperidol binding to the human dopamine D3 receptor: beyond docking through QM/MM refinement toward the design of improved schizophrenia medicines.
    Zanatta G; Nunes G; Bezerra EM; da Costa RF; Martins A; Caetano EW; Freire VN; Gottfried C
    ACS Chem Neurosci; 2014 Oct; 5(10):1041-54. PubMed ID: 25181639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Binding Geometries for Risperidone in Dopamine D3 Receptors: Insights on the Fast-Off Mechanism through Docking, Quantum Biochemistry, and Molecular Dynamics Simulations.
    Zanatta G; Della Flora Nunes G; Bezerra EM; da Costa RF; Martins A; Caetano EW; Freire VN; Gottfried C
    ACS Chem Neurosci; 2016 Oct; 7(10):1331-1347. PubMed ID: 27434874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT
    Saavedra OM; Karila D; Brossard D; Rojas A; Dupuis D; Gohier A; Mannoury la Cour C; Millan MJ; Ortuno JC; Hanessian S
    Bioorg Med Chem; 2017 Jan; 25(1):38-52. PubMed ID: 28029458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor.
    Sahlholm K; Zeberg H; Nilsson J; Ögren SO; Fuxe K; Århem P
    Eur Neuropsychopharmacol; 2016 Mar; 26(3):467-76. PubMed ID: 26811292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of five dopamine receptor subtypes on nuclear factor-kappaB activity in NG108-15 cells and mouse brain.
    Takeuchi Y; Fukunaga K
    J Neurochem; 2004 Jan; 88(1):41-50. PubMed ID: 14675148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
    Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
    Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.